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Abstract
Background: Acute respiratory failure (ARF) remains a common hazardous complication in immunocompromised
patients and is associated with increased mortality rates when endotracheal intubation is needed. We aimed to
evaluate the effect of early noninvasive ventilation (NIV) compared with oxygen therapy alone in this patient
population.
Methods: We searched for relevant studies in MEDLINE, EMBASE, and the Cochrane database up to 25 July 2016.
Randomized controlled trials (RCTs) were included if they reported data on any of the predefined outcomes in
immunocompromised patients managed with NIV or oxygen therapy alone. Results were expressed as risk ratio
(RR) and mean difference (MD) with accompanying 95% confidence interval (CI).
Results: Five RCTs with 592 patients were included. Early NIV significantly reduced short-term mortality (RR 0.62,
95% CI 0.40 to 0.97, p = 0.04) and intubation rate (RR 0.52, 95% CI 0.32 to 0.85, p = 0.01) when compared with
oxygen therapy alone, with significant heterogeneity in these two outcomes between the pooled studies. In
addition, early NIV was associated with a shorter length of ICU stay (MD −1.71 days, 95% CI −2.98 to 1.44, p = 0.008)
but not long-term mortality (RR 0.92, 95% CI 0.74 to 1.15, p = 0.46).
Conclusions: The limited evidence indicates that early use of NIV could reduce short-term mortality in selected
immunocompromised patients with ARF. Further studies are needed to identify in which selected patients NIV
could be more beneficial, before wider application of this ventilator strategy.
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Background
Over the past decades, immunocompromised patients
have become more and more popular, due to advances in
chemotherapy and bone marrow and organ transplantation
[1, 2]. However, these patients are at high risk of a number
of life-threatening complications, especially acute respira-
tory failure (ARF) [3, 4]. A variety of disease processes may
induce ARF, such as immunocompromised-related oppor-
tunistic infections, pulmonary damage secondary to
malignancy, drug-related pulmonary toxicity, or unidenti-
fied causes [5]. Once these patients develop ARF, they
often require intensive care unit (ICU) admission and in-
tubation for mechanical ventilation. Nevertheless, invasive
mechanical ventilation (IMV) in this situation is associated
with a significantly increased mortality rate ranging from
40% to 90% [3, 6]. Therefore, noninvasive ventilation
(NIV), which is administrated without the use of an endo-
tracheal tube, has increasingly attracted attention.
Theoretically NIV can be used as an alternative to
IMV in treating immunocompromised patients. The bene-
ficial effects of NIV in ARF include lung recruitment with
proper use of PEEP, improvement in hypoxia and dyspnea,
and relief of respiratory muscle fatigue [7]. In addition,
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applying NIV in immunocompromised patients can avoid
side effects directly related to endotracheal intubation and
IMV, such as ventilator-associated pneumonia, excessive
sedation, upper-airway injuries and tracheomalacia, thus it
can lead to a better clinical outcome [8].
Although a large number of case series and observa-
tional studies suggest that NIV could reduce the rate of
intubation and thus the associated infections in these
patients [9], the number of randomized controlled trials
(RCTs) is still very limited. The 2011 Canadian guide-
lines made a weak recommendation (grade 2B) favoring
the use of NIV in immunocompromised patients with
ARF [1]. However, this recommendation remains con-
troversial as it is based on only two small early RCTs
[10, 11]. Furthermore, the results of several RCTs have
been reported in recent years, and some of these trials
have a modest sample size, while the conclusions are
inconsistent [12–14].
Therefore, we aimed to perform a systematic review
and meta-analysis of all available RCTs comparing early
use of NIV with oxygen therapy alone in immunocom-
promised patients, to determine if differences exist be-
tween these two strategies in terms of overall mortality,
rate of intubation and length of ICU stay.
Methods
Search strategy and selection criteria
We searched RCTs in MEDLINE, EMBASE, and the
Cochrane database from inception through 25 July 2016
to identify potentially relevant studies. Search terms
included: “non-invasive ventilation,” “noninvasive venti-
lation,” “NIV,” “continuous positive airway pressure,”
“noninvasive mechanical ventilation,” “NIMV,” “BiPAP,”
“CPAP,” “noninvasive positive-pressure ventilation,”
“NPPV,” “hematologic,” “hematological,” “transplant,”
“tumor,” “cancer,” “immunosuppression,” “immunosup-
pressed,” and “immunocompromised”. Our research was
limited to RCTs with no language restriction. Reference
lists of relative articles were also reviewed. Studies were
included if they met the following criteria: (1) study de-
sign: RCT; (2) study population: immunocompromised
adult patients with ARF; (3) intervention: early use of
NIV compared to oxygen therapy alone; and (4) prede-
fined outcomes: mortality, intubation rate, and length of
ICU stay. We excluded studies of patients younger than
age 18 years, and publications available only in abstract
form or as meeting reports. We contacted the authors if
the data on predefined outcomes from their studies were
required.
Data extraction and quality assessment
Two reviewers (H-BH and BX) independently extracted
data from the included studies, such as the name of first
author, year of publication, country, sample size, study
design, setting, treatment algorithms in the study and
control groups, severity of illness, and all predefined
outcomes.
The aforementioned independent reviewers (H-BH
and BX) evaluated the quality of studies using the risk of
bias tool recommended by the Cochrane Collaboration
[15]. We assigned a value of high, unclear, or low to the
following items: sequence generation; allocation conceal-
ment; blinding; incomplete outcome data; selective out-
come reporting; and other sources of bias. As blinding
of caregivers, patients, and family members was impos-
sible in these trials, we considered blinding only at the
data collection level. Discrepancies were identified and
resolved through discussion.
Outcomes and statistical analysis
The primary outcome was short-term mortality. We
defined short-term mortality as ICU, hospital, or 28-day
mortality. If a study reported all of these outcome mea-
sures, the longest observation period was preferred.
Secondary outcomes included intubation rate, length of
ICU stay (defined as the time from admission to ICU
discharge) and long-term mortality defined as mortality
occurring after 3 months of follow-up. Testing the
robustness of our primary outcome and exploring the
influence factors of mortality, we conducted further
analyses by pooled studies with the following: (1) ICU
mortality; (2) hospital mortality; (3) 28-day mortality; (4)
ratio of arterial pressure of oxygen/fraction of inspired
oxygen (PaO2/FiO2); and (5) underlying disease.
The results from all relevant studies were combined to
estimate the pooled risk ratio (RR) and associated 95%
confidence intervals (CIs) for dichotomous outcomes.
As to the continuous outcomes, the mean difference
(MD) and 95% CI was estimated as the effect results.
Some studies reported the median as the measure of
treatment effect, with accompanying interquartile range
(IQR). Before data analysis, we estimated the mean from
the median and standard deviation (SD) from the IQR
using the methods described in previous studies [16].
Heterogeneity was tested by using the I2 statistic. An
I2 < 50% was considered to indicate insignificant hetero-
geneity and a fixed-effect model was used, whereas a
random-effect model was used in cases of significant het-
erogeneity (I2 > 50%). Sensitivity analyses were performed
by excluding trials that potentially biased the results. In
addition, we conducted statistical analyses when data from
at least two RCTs were available. Publication bias was
evaluated by visually inspecting funnel plots when at least
10 studies were included in this meta-analysis. A p value
less than 0.05 was considered statistically significant. All
statistical analyses were performed using STAT Version
12.0 and Review Manager, Version 5.3.
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Result
Study selection
A flowchart of the search strategy and the reasons for
exclusion are shown in Fig. 1. The initial search yielded
104 potentially relevant studies. There were 15 studies
excluded because of duplicates, and 80 studies were ex-
cluded based on reviews of the title and abstract. Thus,
9 full-text studies were read for further evaluation, and
of these, 4 were excluded because they did not report
predefined outcomes or meet our inclusion criteria.
Finally, the remaining 5 RCTs, which enrolled 592
patients, were included in our analysis [10–14].
Study characteristics and quality
The main characteristics of the included RCTs are
described in Table 1 and Additional file 1: Table S1,
while the diagnostic criteria for ARF, treatment
algorithms, and outcome data are described in Tables 2
and 3, and Additional file 1: Table S2. These studies
were published between 2000 and 2015, with sample
sizes ranging from 40 to 374 patients. Three studies
[10, 11, 14] reported a moderate PaO2/FiO2 ratio
(range 100–200) and two studies [12, 13] reported a
mild PaO2/FiO2 ratio (range 200–300) in the enrolled
patients. The immunocompromised patients in the
five studies included patients with cancer (five trials)
[10–14], patients with solid organ transplantation
(two trials) [10, 14], patients participating in trials of
other immunosuppressive agents (two trials) [11, 14], and
patients with acquired immunodeficiency syndrome (one
trial) [11]. Noninvasive pressure support ventilation
(NIPSV) mode was used in four trials, with variable levels
of positive end-expiratory pressure (PEEP) ranging from 2
to 10 cmH2O according to the target of oxygenation and
patient tolerance [10, 11, 13, 14], whereas continuous
positive airway pressure (CPAP) of 10 cmH2O was used in
one trial [12]. The Cochrane risk of bias score varied
across the studies (Fig. 2).
Primary outcome
Mortality was reported in all five RCTs. Short-term
mortality data were available in four studies, [10–12, 14]
In pooled analysis the use of NIV was associated with a
significant reduction in short-term mortality (four trials;
RR 0.62, 95% CI 0.40 to 0.97, p = 0.04), with significant
heterogeneity among the studies (I2 = 64%) (Fig. 3a).
Therefore, we conducted sensitivity analyses to explore
potential sources of heterogeneity. Exclusion of the trial
by Squadrone and colleagues [12] significantly decreased
the heterogeneity without altering the result (three
trials; RR 0.76, 95% CI 0.59 to 1.00, p = 0.047; I2 =
17%) [10, 11, 14]. In sensitivity analysis, both ICU
and hospital mortality rates were significantly lower in the
NIV group, while subgroup analysis confirmed a consist-
ent reduction in mortality in patients with moderate
hypoxemia, and patients with cancer or solid organ
transplantation. However, use of NIV did not exhibit any
beneficial effect on mortality in patients receiving im-
munocompromised agents or patients with mild hypox-
emia (Table 4).
Secondary outcomes
Use of NIV was associated with significant reduction in
the intubation rate (five trials, RR 0.52, 95% CI 0.31 to
0.87, p = 0.01; I2 = 68%) (Fig. 3b) and length of ICU
stay (three trials, MD −1.71 days, 95% CI −2.98 to −0.44,
p = 0.008; I2 = 0%)(Fig. 3c) [10, 11, 14], but not a decrease
in long-term mortality (two trials; RR 0.92, 95% CI 0.74 to
1.15, p = 0.46) (Fig. 3d). [13, 14] There was significant het-
erogeneity in the outcome of intubation rate between the
pooled RCTs. Further exclusion of any single RCT did not
materially change the overall combined RR, which ranged
from 0.42 (95% CI 0.24 to 0.74, p = 0.003) to 0.61 (95% CI
0.37 to 1.00, p = 0.05), while heterogeneity still existed
(I2 range 46–75%).
Discussion
Our meta-analysis illustrated that early use of NIV could
effectively reduce short-term mortality in immunocom-
promised patients with ARF when compared with oxygen
Fig 1 Selection process for randomized controlled trails (RCTs) included
in the meta-analysis


















































































































































































































































































































































































































































































































































































































































Huang et al. Critical Care  (2017) 21:4 Page 4 of 9
therapy alone. In addition, the NIV strategy was associated
with a reduction in the rate of endotracheal intubation
and length of ICU stay.
Although our results are encouraging, several import-
ant issues merit detailed discussion. First, significant
heterogeneity was observed between pooled studies in
the primary outcome. This is not surprising, given the
differences in the diagnostic criteria for ARF, treatment
algorithms, and underlying diseases. Our sensitivity ana-
lyses showed that the trial by Squadrone and colleagues
[12] probably contributed to the observed heterogeneity.
Unlike other included trials, Squadrone and colleagues
enrolled immunocompromised patients without a
diagnosis of pneumonia, infection, or sepsis. Of note,
these patients had a higher PaO2/FiO2 ratio, and were
managed by CPAP rather than by NIPSV. After exclud-
ing this trial, the pooled result of the remaining studies
still showed a reduction in mortality. Furthermore, we
also demonstrated a significant reduction in the intub-
ation rate and length of ICU stay in the NIV group,
which added robustness to our primary outcome.
Second, our findings contradicted the results of the
two latest RCTs [13, 14]. These two trials, although in-
cluded in our meta-analysis, did not report a significant
difference in clinical outcome (e.g. short-term or long-
term mortality and intubation rate) among inpatients
Table 2 Definition of criteria for acute hypoxemic respiratory failure and study treatment algorithm
Study Criteria for acute hypoxemic respiratory failure Study treatment algorithms
Antonelli et al. 2000 [10] RR >35/min; PaO2/FiO2 < 200 while breathing
oxygen; active contraction of accessory muscles
of respiration or paradoxical abdominal motion
Ventilation algorithm: NIV via facemask; pressure support
adjusted to obtain a Vt of 8–10 mL/kg, RR <25/min, the
disappearance of accessory muscle activity and patient
comfort. Control algorithm: patients received oxygen
supplementation via a Venturi mask starting with an
FiO2≥ 0.4, and adjusted to SpO2 > 90%
Hilbert et al. 2001 [11] Pulmonary infiltrates and fever; severe dyspnea
at rest; RR >30/min; PaO2/FiO2 < 200 while
breathing oxygen
Ventilation algorithm: NIV via facemask; pressure support
adjusted to obtain a Vt of 7–10 mL/kg; RR <25/min. PEEP
was increased by 2 cmH2O, up to 10 cmH2O, adjusted to
FiO2≤ 65% and SpO2 > 90%. Control algorithm: patients
received oxygen through a Venturi mask. The rate of
administration of oxygen was adjusted to SpO2 > 90%
Squadrone et al. 2010 [12] Bilateral pulmonary infiltrates; SpO2 < 90% with
room air; RR >25/min; respiratory symptom
duration <48 h
Ventilation algorithm: CPAP via facemask or helmet at 10
cmH2O and FiO2 = 50%. Control algorithm: patients
received oxygen through a Venturi mask
Wermke et al. 2012 [13] RR >25/min; PaO2/FiO2 < 300 or SpO2 < 92%
with room air
Ventilation algorithm: NIV via facemask; with pressure
support of 15 cmH2O and an initial PEEP of 7 cmH2O;
adjustments were according to capillary blood gas analysis
and tolerance of patient. Control algorithm: patients
received oxygen via nasal insufflation or full face mask
initially set to 3 L/min. Adjustment of oxygen flow was left
to physician’s discretion
Lemiale et al. 2015 [14] PaO2 < 60 mmHg with room air; RR >30/min, or
labored breathing or respiratory distress or
dyspnea at rest; respiratory symptom duration
<72 h
NIV algorithm: NIV via facemask; pressure support adjusted
to obtain a Vt of 7–10 mL/kg ideal body weight; with an
initial PEEP 2–10 cmH2O. The FiO2 and PEEP were adjusted
to SpO2 ≥ 92%. Control algorithm: oxygenation modalities
and the use of HFNC at clinician’s discretion
PaO2/FiO2 ratio of arterial pressure of oxygen/fraction of inspired oxygen, SpO2 pulse arterial oxygen saturation, CPAP continuous positive airway pressure,
HFNC heated and humidified high flow oxygen delivered by nasal cannula, ICU intensive care unit, PEEP positive end expiratory pressure, NIV noninvasive
ventilation, RR respiratory rate, Vt tidal volume















NIV Ctrl NIV Ctrl NIV Ctrl NIV Ctrl NIV Ctrl NIV Ctrl NIV Ctrl
Antonelli et al. 2000 [10] 20 50 35 55 NR NR NR NR 100 71.4 20 70 7 ± 5 10 ± 6
Hilbert et al. 2001 [11] 38.5 69.2 50 80.8 NR NR NR NR 100 100 46.2 76.9 7 ± 3 9 ± 4
Squadrone et al. 2010 [12] NR NR 15 75 NR NR NR NR 100 100 10 70 0 (0–28) 28 (0–28)
Wermke et al. 2012 [13] NR NR NR NR NR NR 39 32 100 100 14.3 25 NR NR
Lemiale et al. 2015 [14] 20.9 24.6 30.9 34.4 24.1 27.3. 39.6 45.3 NR NR 38.2 44.8 7 (3–16) 6 (3–16)
Ctrl control, ET endotracheal intubation, ICU intensive care unit, NIV noninvasive ventilation, NR not reported
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assigned to early NIV compared with oxygen therapy
alone. Wermkeet al. [13] enrolled patients with mild
hypoxemia, as suggested by a mean PO2/FiO2 ratio of
250 to 300. Moreover, 36.4% (16/44) of patients in the
control group received NIV as a rescue therapy. The
high crossover rate might have masked the beneficial
effect, if any, of NIV in immunocompromised patients
with ARF. This trial might also contribute to the
negative findings in the subgroup of mild hypoxemia. In
comparison, in the study of Lemiale and colleagues [14],
a high-flow nasal cannula (HFNC) was used in both
groups at the discretion of treating physicians.
Interestingly, HFNC was used more often in the
oxygen group than in the NIV group (44% vs. 31%,
p = 0.01). HFNC is a new technique that may deliver
up to 100% humidified oxygen at a high flow rate.
The advantages of HFNC include a high fraction of
inspired oxygen to improve oxygenation, generation
of flow-dependent PEEP (2–5 cmH2O) to improve alveo-
lar recruitment, enhanced washout of nasopharyngeal
dead space, and greater comfort in patients requiring
oxygen therapy [17]. Several studies have shown that
compared with conventional oxygen therapy, HFNC in
immunocompetent patients with ARF could improve
respiratory parameters, comfort and patient tolerance
[18–20]. Moreover, in an observational cohort study of
immunocompromised ICU patients with ARF, Coudroy
and colleagues reported that use of HFNC was associated
with a significant reduction in intubation rate and 28-day
mortality compared to NIV (35% vs. 55%, p = 0.04, and
20% vs. 40%, p = 0.02, respectively) [21]. As a result, the
use of HFNC could have greatly reduced the demand for
IMV in control group, thereby diluting the benefits of
NIV in these patients. More than this, it may also explain
why there was no reduction in long-term mortality in the
pooled analysis of patients in these two trials only. It is
also noteworthy that in the study by Lemiale and col-
leagues [14], the overall mortality rate was much lower
than in the other included RCTs (hospital mortality 32.6%
vs. 45–65%). Thus, this study might provide a clue to the
potential benefits of HFNC, or HFNC in combination
with NIV, over NIV alone. Nevertheless, such a hypothesis
should await validation by a large scale, well-designed
RCT in the future.
Third, extremely high mortality rates were reported in
immunocompromised patients who did not respond to
conventional oxygen therapy or to NIV (Table 3); these
rates were even higher than the mortality rate of 70–80%
Fig 2 Risk-of-bias analysis
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that is widely reported in previous studies [22, 23]. Despite
the fact that the exact reasons remain to be clarified, such
high mortality might support the recommendation against
the use of IMV in this vulnerable patient population, thus
favoring NIV as the first-line choice of therapy [1].
Finally, we also found that early use of NIV was
associated with a significant reduction in the length of
ICU stay. This encouraging result has added robustness
to the conclusion that early NIV strategy is effective in
immunocompromised patients with ARF. Although in
clinical practice, ICU discharge is not always determined
by the patient condition and needs to be individualized
[24]; the less likely that a patient requires tracheal intub-
ation, the more likely that physicians feel comfortable
about the patient being discharged from ICU.
The current meta-analysis has provided evidence to
support and expand the weak suggestion in the 2011
Canadian guidelines [1], i.e. use of noninvasive positive-
pressure ventilation (NPPV) in immunocompromised pa-
tients with ARF. However, this study has some limitations.
Fig 3 Effects of noninvasive ventilation (NIV) on immunocompromised patients. Forest plot showing the effect of NIV on short-term mortality (a),
incidence of intubation rate (b), length of intensive care unit stay (c) and long-term mortality (d). OT oxygen therapy
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First, only five RCTs were included in the current
meta-analysis, while four of them had a sample size
of 40 to 86 patients, which more likely resulted in
overestimation of the treatment effect than in studies
with larger sample sizes. Second, significant hetero-
geneity was observed in some of our outcomes. There
were remarkable differences among the included trials
in the adopted definition of ARF, timing and duration
of oxygen therapy or NIV, and indications for endo-
tracheal intubation, which might lead to the observed
heterogeneity, and further impair the robustness of our
findings. Third, the uneven distribution of different under-
lying diseases among the included studies might also exert
a prognostic value [4, 25, 26]. Although predefined
subgroup analyses had been performed, the results should
be interpreted with caution due to the small number of
patients in some disease categories, i.e. patients receiving
immunocompromised drugs or patients with acquired
immunodeficiency syndrome.
Conclusions
In summary, based on the available data, our results
demonstrate that compared with oxygen therapy, early
respiratory support with NIV would significantly reduce
mortality, intubation rate and length of ICU in immuno-
compromised patients with ARF of various origins.
Large-scale, well-designed RCTs will be needed to define
the subgroup of patients that are most likely to benefit
from this strategy.
Key messages
 Early use of NIV significantly reduced overall
mortality, intubation rate and length of ICU stay in
immunocompromised patients with ARF of various
origins, when compared with administration of
oxygen therapy.
 Further larger adequately powered RCTs are
warranted to identify in which selected patients
NIV could be more beneficial before the wider
application of this ventilator strategy.
Additional file
Additional file 1: Table S1. Characteristics of patients enrolled in the
included studies, categorized by type of immunosuppression and cause
for acute respiratory failure. Table S2. Summary of mortality and
intubation rates in patients categorized by type of immunosuppression
and cause of acute respiratory failure. (DOCX 31 kb)
Abbreviations
ARF: acute respiratory failure; CI: confidence interval; CPAP: continuous
positive airway pressure; HFNC: high-flow nasal cannula; ICU: intensive care
unit; IMV: invasive mechanical ventilation; IQR: interquartile range; MD: mean
differences; NIMV: noninvasive mechanical ventilation; NIPSV: noninvasive
pressure support ventilation; NIV: noninvasive ventilation; NPPV: noninvasive
positive-pressure ventilation; PaO2/FiO2: ratio of arterial pressure of oxygen/
fraction of inspired oxygen; PEEP: positive end-expiratory pressure;
RCT: randomized controlled trial; RR: risk ratio; SD: standard deviation
Funding
No external funding was required for this research.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
H-BH and BX searched the scientific literature and drafted the manuscript.
J-DL contributed to conception, design, and data interpretation. G-YL helped
to collect the data and performed statistical analyses. BD contributed to
conception, design, data interpretation, manuscript revision for critical
intellectual content, and supervision of the study. All authors read and
approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Medical ICU, Peking Union Medical College Hospital, Peking Union Medical
College and Chinese Academy of Medical Sciences, 1 Shuai Fu Yuan, Beijing
100730, People’s Republic of China. 2Department of Critical Care Medicine,
the First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road,
Fuzhou 350000, People’s Republic of China. 3Critical Care Medicine Center,
the PLA 302 Hospital, No. 100 Xisihuanzhong Road, Fengtai District, Beijing
100039, People’s Republic of China.
Received: 13 October 2016 Accepted: 8 December 2016












Short-term mortality 4 506 82 of 257 (31.9%) 110 of 249 (44.2%) 0.73 (0.58, 0.91) 64% 0.04
ICU mortality 3 466 54 of 237 (22.8%) 73 of 229 (31.9%) 0.72 (0.53, 0.97) 33% 0.03
Hospital mortality 4 506 82 of 257 (31.9%) 110 of 249 (44.2%) 0.73 (0.58, 0.91) 64% 0.04
Patients with PaO2/FiO2 < 200 3 541 92 of 228 (40.4%) 114 of 227 (50.2%) 0.77 (0.61, 0.98) 13% 0.03
Patients with PaO2/FiO2 > 200 2 126 29 of 62 (46.8%) 45 of 64 (70.3%) 0.46 (0.09, 2.34) 88% 0.35
Patients with diagnosis of cancer and transplantation 5 507 85 of 258 (32.9%) 113 of 249 (45.4%) 0.68 (0.48, 0.97) 58% 0.03
Patients with diagnosis of drug-related immunosuppression 2 81 7 of 33 (21.2%) 5 of 30 (16.7%) 0.95 (0.48, 1.87) 0% 0.37
ICU intensive care unit, NIV noninvasive ventilation, PaO2/FiO2 ratio of arterial pressure of oxygen/fraction of inspired oxygen
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